Infectious Disease Therapeutics Market Was Valued At USD 86.2 Billion By 2025 : Grand View Research Inc.

Infectious Disease Therapeutics Market Was Valued At USD 86.2 Billion By 2025 : Grand View Research Inc.

“Grand View Research, Inc. – Market Research And Consulting”
According to report published by Grand View Research,Rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are likely to be the factors responsible for growth of Infectious Disease Therapeutics market.

According to a report,” Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2018 – 2025 ” published by Grand View Research, Inc., The global infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

Key Takeaways from the report:

 The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally.

North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases.

The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period.

Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH.

Infectious disease therapeutics market, by disease type, 2014 - 2025 (USD Billion)

Browse More Reports in Pharmaceuticals Industry: 

Liposomal Doxorubicin Market The market is experiencing growth due to rising breast & ovarian cancer cases and growing awareness regarding the benefit of liposomal doxorubicin formulation over the traditional doxorubicin.

Hormone Replacement Therapy (HRT) Market :Rising incidences of hormonal imbalance disorders and increasing geriatric and the neonatal population suffering from these diseases are expected to promote growth of Hormone Replacement Therapy (HRT) Market.

Top six infectious disease therapeutics market, by region, 2016 (%)

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Grand View Research has segmented the infectious disease therapeutics market on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2014 – 2025)

  • HIV

    • Emtriva

    • Aptivus

    • Isentress

    • Lexiva/Telzir

    • Selzentry

    • Tivicay 

    • Atripla

    • Complera

    • Genvoya

    • Odefsey

    • Stribild

    • Truvada

    • Triumeq

    • Descovy

    • Vitekta

    • Others

  • Influenza

    • Relenza

    • Tamiflu 

    • Rapivab 

    • Others

  • TB

    • Sirturo

    • Others

  • Malaria

    • Coartem

    • Others

  • HPV

  • Hepatitis

Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States